92% of drugs that pass animal tests fail in humans. 🚫
The cost? Years of research + billions wasted.
Human-on-chip models like Quasi Vivo® give data that actually translates.
#DrugDiscovery #OrganOnChip #MPS

Your body is a system, not isolated parts.
Quasi Vivo® connects multiple organs under gentle, lifelike flow, revealing interactions single-organ models miss.
Model the whole, not just the parts.

#OrganOnChip #HumanOnChip #MPS

Metastasis causes 90% of cancer deaths, yet remains incredibly hard to study because lab models can't accurately replicate tumour spread between human organs.

A new approach could finally change this.

#CancerResearch #Metastasis #OrganOnChip #Innovation

Every 90-day drug safety study can sacrifice 80 animals—but there’s a better way. Kirkstall's Quasi Vivo® offers low-shear, human-cell systems, accurately modeling human biology without animals.

Discover ethical, reliable research at: kirkstall.com

#AnimalFreeResearch #QuasiVivo #OrganOnChip

Pushing organ-on-a-chip from cool demo to everyday research tool takes shared standards everyone can trust. 🧬⚙️

Kirkstall dives into why harmonised protocols and familiar well-plate formats will boost reproducibility and cut reliance on animal tests.

kirkstall.com/supporting-e...

Perfusion flow cell culture brings lab experiments closer to real-life conditions. 📚 One key insight: Cells thrive when nutrient flow and waste removal mimic the body's natural environment.

🔗Our article explains why this matters for your research:
kirkstall.com/an-introduct...

MPSs bridge critical gaps between lab models and human biology. To unlock their full potential, the field must focus on:

• Multi-organ integration
• Patient-derived cells for personalised insights
• Clinical validation for real-world relevance

#MPS #PrecisionMedicine

🕰️ New review shows how “ageing-on-a-chip” tech can model decades of biology in weeks. Low-shear perfusion & multi-organ flow are key — exactly what Quasi Vivo’s plug-and-play milli-fluidics deliver. Ready to study senescence without mice? 👇 advanced.onlinelibrary.wiley.com/doi/10.1002/...

📚 New MPS Roadmap: A fresh review (Hartung et al., ALTEX) outlines challenges holding back organ-on-chip adoption: need for standards, validation benchmarks, regulatory clarity, data sharing… and calls for global collaboration to solve them. Essential read for OOC folks! 🔗 doi:10.14573/altex.2504091

🔬 New Nature study: an 18-organ “body-on-a-chip” links heart, liver, brain & more via microfluidic blood flow + excretory loop. Stable for 2 months, reproducing human PK & toxicity across tissues—huge leap for complex in-vitro testing

www.nature.com/articles/s41...

🎯 From liver & brain to tumour microenvironment —Quasi Vivo does it all. Modular circuits 🔁 link multiple organs to realistically study systemic diseases like diabetes right on your benchtop. Healthy tissues, predictive human data, and powerful simplicity in one system.

🧱 Imagine organ-on-a-chip tech as simple as a LEGO kit! Quasi Vivo’s plug‐and‐play, modular design lets you set up advanced 3D cell cultures in minutes. ILow-shear flow keeps tissues thriving, minus the hassle of complex fabrication. Explore more at kirkstall.com

AI-driven drug discovery is rapidly generating countless new molecules. Microphysiological systems are essential to quickly and reliably evaluate their safety and effectiveness, accelerating precision medicine and advancing research.

📖 pmc.ncbi.nlm.nih.gov/articles/PMC...

🐾 It’s time to replace animal testing!

Join us at the Best Practice in Non-Animal Methods Conference 2025, where Prof. Malcolm Wilkinson will tackle the barriers to human-relevant research.

March 26-27 | 📍 York
Register now 👉 humanspecificresearch.org/our-2025-joi...
#HumanRelevantScience

Are research tools getting too complex for their own good?

MPSs could transform drug discovery, but many are too costly, complex, or specialised for everyday labs.
We believe that better science starts with:
✔️ Simpler workflows
✔️ Realistic costs
✔️ Usability first

🚀 New tech doesn’t adopt itself.

Microphysiological systems must earn their place by proving:
✅ Human relevance
✅ Clear application
✅ Validation & benchmarking

We are committed to these criteria, ensuring Quasi Vivo meets the standards needed for widespread adoption.

We know more about curing diseases in animals than in humans. With 90% of drugs failing in human trials after animal testing, it’s clear: animal models are outdated, inefficient, and unethical. Human-relevant systems like #QuasiVivo can save human lives and reduce animal testing.

🚨 Exciting update! Yesterday, Malcolm Wilkinson gave an inspiring talk at the #BITEG conference in Sheffield on creating physiologically relevant in vitro models. 🧬 Huge thanks to the organizers for a great event! 💡 #Kirkstall #InVitroModels #TissueEngineering #RegenerativeMedicine

Discover how Kirkstall’s bioreactor is enabling groundbreaking research on pancreatic cancer at @uclofficial.bsky.social. Professor Eirini Velliou explains how her team is studying cell behaviour and chemotherapy responses using advanced in vitro models. Full video: kirkstall.com/quasi-vivo-c...

Dr. Malcolm Wilkinson, founder of Kirkstall Ltd, will keynote at the BiTEG conference on Jan 16th at @sheffielduni.bsky.social.

He’ll explore the future of in-vitro models & their role in replacing animal testing.

Register here 🎉: onlineshop.shef.ac.uk/conferences-...

🌟 We’re excited to join the Bluesky community! At Kirkstall, we’re advancing research and industry with Quasi Vivo® systems, providing ethical, innovative alternatives to animal testing.

#DrugDiscovery #OrganOnChip #Innovation #PersonalisedMedicine #MicrophysiologicalSystems